GlassScriptPhysician profile
Roy H Hinman
NPI 1760595821
$4,762.56
in general payments reported to CMS, 2019-2025
32 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,072 · 2020: $629 · 2021: $738 · 2022: $650 · 2023: $296 · 2024: $242 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $673.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,363.89 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $588.00 | 2019-2025 | Wegovy |
| Semler Scientific, INC. | $407.33 | 2019 | |
| Janssen Pharmaceuticals, INC | $308.97 | 2019-2022 | |
| Depuy Synthes Sales INC. | $262.46 | 2019-2024 | Monovisc, Orthovisc |
| Philips North America LLC | $213.48 | 2022 | |
| Astellas Pharma US INC | $191.95 | 2019-2021 | |
| Pfizer INC. | $167.17 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.06 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $136.34 | 2019 | |
| Abiomed | $125.43 | 2021 | |
| Boston Scientific Corporation | $123.74 | 2019 | |
| Abbott Laboratories | $113.37 | 2020 | |
| Novartis Pharmaceuticals Corporation | $94.16 | 2019-2022 | |
| Biosense Webster, INC. | $82.23 | 2025 | Carto 3 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $60.51 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.33 | 2019-2022 | |
| Corcept Therapeutics | $38.58 | 2021 | |
| Sanofi-Aventis U.S. LLC | $35.53 | 2019 | |
| Inspire Medical Systems, INC. | $34.54 | 2024 | Inspire |
| Bridgebio Pharma, INC. | $30.49 | 2025 | Attruby |
| Melinta Therapeutics, LLC | $29.14 | 2019-2020 | |
| Orexo US, INC. | $20.09 | 2021 | |
| Amgen INC. | $19.26 | 2019 | |
| Bioventus LLC | $18.43 | 2023 | Supartz Fx Sodium Hyaluronate |
| Medtronic, INC. | $18.22 | 2024 | Intellis Adaptivestim |
| Si-Bone, INC. | $17.24 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.98 | 2023 | Camzyos |
| Amarin Pharma, INC. | $15.78 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $14.64 | 2021 | |
| Hikma Pharmaceuticals USA | $14.39 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Hinman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.